EMCURE

Emcure Pharmaceuticals Financial Results

₹1,915.30-0.37%
Market cap
₹36,312 crore
P/E
35.9
P/B
7.34
ROE
19.7%
Dividend yield
0.19%

For the year ended Mar 2023, Emcure Pharmaceuticals reported revenue of ₹5,931 crore and net profit of ₹562 crore, against ₹6,582 crore and ₹528 crore a year earlier.

Emcure Pharmaceuticals annual profit and loss

Financial years, newest first. TTM = trailing twelve months.

Emcure Pharmaceuticals annual profit and loss (₹ crore)
ItemMar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue5,9316,5827,8089,1169,683
Expenses4,7305,3526,3397,3277,791
Operating profit1,2011,2301,4691,7891,893
Operating margin %20%19%19%20%20%
Other income-3011273771
Interest163201140123148
Depreciation260312384415425
Profit before tax7477279711,2871,390
Tax %25%27%27%27%27%
Net profit5625287079411,019
EPS (₹)28.1326.3535.9648.7653.35
Dividend payout %—————

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Emcure Pharmaceuticals financial results — frequently asked questions

What is Emcure Pharmaceuticals' annual revenue and net profit?

For the financial year ended Mar 2023, Emcure Pharmaceuticals' revenue was ₹5,931 crore and net profit ₹562 crore; net profit rose 6.44% from ₹528 crore in Mar 2024.

How fast has Emcure Pharmaceuticals grown over three years?

From Mar 2026 to Mar 2023, Emcure Pharmaceuticals' revenue grew at a compound annual rate of -13.3% and net profit at -15.8%. Past growth does not indicate future results.

What is the EPS of Emcure Pharmaceuticals?

Annual EPS for Mar 2023 was ₹28.13.

Are these figures consolidated or standalone?

They are consolidated figures as reported by the company, in ₹ crore. Trailing-twelve-month and half-year columns are labelled separately and are not counted as financial years.

Same Data For Peers

Trade Emcure Pharmaceuticals With ATS

Track EMCURE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.